Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
MA

NASDAQ · MAIA

MAIA Biotechnology, Inc.

Healthcare · Biotechnology

$1.10

Down-$0.08 (-6.78%)

Updated Nov 2, 2026, 8:20 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
60.55M
P/E ratio
-3.06
Dividend yield
0.00%
52-week range
$0.87 – $3.19
Volume
313.66K
Avg. volume
630.4K

Price performance · MAIA

MAIA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

MAIA closed at $1.10 after 20 trading sessions, down 6.78% for the selected period.

Last close
$1.10
Period change
-6.78%
Period low
$1.07
Period high
$1.22
Daily close
View OHLC price history
MAIA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$1.16$1.17$1.10$1.10313.66K
Oct 29, 2026$1.17$1.22$1.16$1.18172.02K
Oct 28, 2026$1.16$1.18$1.11$1.16236.23K
Oct 27, 2026$1.14$1.185$1.10$1.17301.11K
Oct 26, 2026$1.15$1.15$1.10$1.11279.98K
Oct 23, 2026$1.13$1.15$1.12$1.15141.09K
Oct 22, 2026$1.14$1.15$1.12$1.1392.28K
Oct 21, 2026$1.13$1.15$1.06$1.14107.87K
Oct 20, 2026$1.08$1.13$1.07$1.12184.54K
Oct 19, 2026$1.09$1.10$1.06$1.07799.14K
Oct 16, 2026$1.13$1.15$1.08$1.10363.52K
Oct 15, 2026$1.10$1.15$1.10$1.12296.93K
Oct 14, 2026$1.15$1.16$1.10$1.12628.7K
Oct 13, 2026$1.18$1.18$1.15$1.16277.47K
Oct 12, 2026$1.22$1.22$1.16$1.18229.96K
Oct 9, 2026$1.16$1.24$1.16$1.22375.3K
Oct 8, 2026$1.15$1.16$1.13$1.15677.14K
Oct 7, 2026$1.17$1.22$1.16$1.18359.68K
Oct 6, 2026$1.20$1.21$1.175$1.19227.16K
Oct 5, 2026$1.17$1.21$1.17$1.18531.01K

Latest MAIA news

The latest Smart Investors Daily articles mentioning MAIA.

Stock researchCompany · Overview

MAIA research

Overview

Company profile and research snapshot.

Company profile

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.38
Implied upside
—
Analysts
7
MAIA recent ratings
DateFirmRatingTarget
Feb 21, 2023Noble Capital MarketsOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI

Yahoo · Sep 23, 2026

MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By